Alzheimer's disease therapy - clinical trials
Professor Donna Wilcock discusses the process of going from a mouse model to human trials for testing the amyloid beta immunization for Alzheimer's disease.
Right now, as of today [November, 2008], the drug companies are in phase II and phase III clinical trials of something a little more complex than the a-beta [amyloid beta] vaccination, which is to directly administer anti-a-beta antibodies to people. The idea is that this is a safer approach than a vaccination approach because you can withdraw treatment if you see any adverse effects. So, the antibody â€“ and we call this passive immunization â€“ passive immunization is in phase II to phase III, and there are at the moment, to my understanding, three drug companies with three different antibodies in trials. And then the a-beta vaccination approach, which is an active vaccination, this approach is in very early phase II trials right now.
alzheimer, treatment, vaccine, immunization, phase, human, clinical, trial, antibody, vaccination, therapy, donna, wilcock
PBS's 'Secret Life of the Brain' reviews research on the prevention and treatment of Alzheimer's disease.
Professor Donna Wilcock discusses an exciting finding from her research group that uses immunotherapy to prevent neurofibrillary tangles in mice.
Researchers reported progress on several potential drug therapies for people with Alzheimer's disease.
Dr. Sumner discusses the clinical trial process for SMA antisense oligonucleotide therapy.
Professor Donna Wilcock discusses a new biological technique for diagnosing Alzheimer's disease using PET neuroimaging.
Professor Donna Wilcock explains that Alzheimer's disease is diagnosed clinically by a battery of tests that can take a full day to administer.
Bruce Stillman, Ph.D. is president and chief executive officer of Cold Spring Harbor Laboratory, explains that there are two adaptive immune responses, and those immune responses adapt to changes in cells in our body whether they be by infection or other.
Professor Donna Wilcock dscusses the cholinergic hypothesis of Alzheimer's disease, which focuses on cholinergic neurons. The hypothesis has not been supported.
An overview of Alzheimer's disease-related content on Genes to Cognition Online.
Professor Donna Wilcock explains that Aricept can only provide short-term benefit in treating Alzheimer's disease.